SecBot SecBot
8-K ·Filed Apr 9, 2026

ZNTL

Zentalis Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago SEC0001725160-26-000017
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The dose selection represents a significant advancement in the clinical development of azenosertib, supporting the company's registration-intended path. The expanded trial design and confirmatory Phase 3 trial initiation suggest Zentalis is positioning azenosertib for potential accelerated approval. The extended cash runway provides sufficient funding for expected milestones, reducing near-term financing risk.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.42
T+0 close · Apr 9, 2026 · via day close
Latest settled
+6.79%
T+60 · $4.72
Vs SPY
−3.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 9 $4.42entry
  2. T+1 · 7mo ago +49.55%α +49.61% · $6.61
  3. T+5 · 7mo ago +13.57%α +10.39% · $5.02
  4. T+20 · 6mo ago −5.43%α −13.00% · $4.18
  5. T+60 · 4mo ago +6.79%α −3.99% · $4.72
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zentalis Pharmaceuticals announced the selection of 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer based on interim data from the DENALI Part 2a trial. The company also announced an expanded trial design (Part 2c) and expects to complete enrollment and provide a topline readout by year-end 2026. The company maintains its cash runway into late 2027.

Key Facts

  • Selected 400mg QD 5:2 as optimal dose for azenosertib based on interim data from DENALI Part 2a
  • Demonstrated meaningful and clearly differentiated response rate at 400mg vs 300mg dose
  • Observed comparable safety profiles between dose groups with improved discontinuation rates
  • Expanded DENALI trial to include Part 2c cohort for patients previously treated with taxane-containing regimens
  • ASPENOVA Phase 3 confirmatory trial expected to initiate in Q2 2026
  • Topline readout from DENALI Part 2 expected by year-end 2026
  • Cash runway extended into late 2027 based on $245.9M in cash, cash equivalents, and marketable securities as of December 31, 2025

Financial Impact

No direct financial impact disclosed, but successful development could address a $21,500 patient population market opportunity

cash runwayclinical development timeline

Risk Factors

  • Clinical trial results may not support accelerated approval
  • Phase 3 ASPENOVA trial may not verify clinical benefit, potentially leading to FDA withdrawal of accelerated approval
  • Competitive landscape in platinum-resistant ovarian cancer

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001725160-26-000017
Exhibit: ex992doseconfirmationpress.htm0001725160-26-000017
Document: zntl-20260409.htm0001725160-26-000017
Document: 0001725160-26-000017-index-headers.html0001725160-26-000017
Document: 0001725160-26-000017-index.html0001725160-26-000017
Document: 0001725160-26-000017.txt0001725160-26-000017

Track record

18 reports on ZNTL

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
  2. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
  4. Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
  5. Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
  6. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
  7. Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
  9. Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
  10. May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 9, 2026